Hookipa Pharma debuts IPO
New York and Austria-based Hookipa Pharma, a developer of immunotherapeutics, has raised $84 million for its IPO after pricing its 6 million shares at $14 per share. The stock began trading April 18, 2019 on the NASDAQ under the ticker symbol “HOOK." BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the lead underwriters. Hookipa's pre-IPO backers included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
18 April 2019•3 mins read
